We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3908:HKEXChina International Capital Corp. Ltd. Class H Analysis

Data as of 2026-06-04 - not real-time

HK$19.12

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

China International Capital Corporation (3908.HK) trades at HK$19.12, well below its DCF fair value of HK$492.6, implying a ~46% upside. The stock sits just above the computed support of HK$18.91 and below resistance at HK$21.92, with the 20‑day SMA (HK$20.44) still higher than the current price, indicating short‑term pressure. Technical signals are mixed: the MACD is bearish (line –0.20 vs signal –0.01) and the RSI sits at 36, hinting at possible oversold conditions. Volatility over the past 30 days is elevated at ~31 % while beta is modest (~0.73), suggesting the share moves less than the market but can swing sharply. Fundamentals are strong: revenue has surged 63 % YoY, operating margin exceeds 51 %, and the PE of 8.8 is far below the industry average of 17. Dividend yield of 1.0 % is supported by a low payout ratio of 9.6 %.
Despite a high debt‑to‑equity ratio of 282 %, the balance sheet is cushioned by HK$532 bn of cash, giving ample liquidity. The company’s low price‑to‑book (0.78) and strong cash flow generation (HK$88 bn operating cash) reinforce the undervalued narrative. Analyst consensus is a “strong buy” with a median target of HK$28.3, reinforcing the upside potential. The combination of robust growth, attractive valuation, and sustainable dividend makes the stock a compelling buy across horizons. However, decreasing volume and regulatory headwinds in China add a modest risk element. Investors should consider a position now while monitoring support levels and policy developments.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • MACD bearish but RSI near oversold
  • Price near support level
  • Decreasing volume suggests caution

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • 63% revenue growth YoY
  • PE 8.8 vs industry 17 indicating value
  • Sustainable dividend with low payout

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong cash position relative to debt
  • Strategic position in Chinese capital markets
  • Long‑term DCF upside and analyst buy consensus

Key Metrics & Analysis

Financial Health

Revenue Growth63.50%
Profit Margin35.43%
P/E Ratio8.8
ROE8.89%
ROA1.47%
Debt/Equity281.62
P/B Ratio0.8
Op. Cash FlowHK$88.2B
Industry P/E17.0

Technical Analysis

TrendNeutral
RSI36.3
SupportHK$18.91
ResistanceHK$21.92
MA 20HK$20.44
MA 50HK$19.66
MA 200HK$20.38
MACDBearish
VolumeDecreasing
Fear & Greed Index93.93

Valuation

Fair ValueHK$492.60
Target PriceHK$27.99
Upside/Downside46.38%
GradeUndervalued
TypeBlend
Dividend Yield1.03%

Risk Assessment

Beta0.73
Volatility30.73%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.